WEST PHARMACEUTICAL SERVICES INC Q3 FY2026 earnings call

• CEO Michele Lagarde highlighted a strong mission-driven culture and successful integration of automation at the Ashweiler site in Germany to unlock efficiency.
• Customer feedback confirms West is a preferred partner due to deep technical and regulatory expertise, with plans to elevate relationships from operational to strategic levels for better demand planning.
• HPP components business is a standout performer, driven by robust biologics growth, strength in GLP-1s, and positive product mix shifts.
• Annex I regulations are driving HPP upgrades in Europe, with increasing activity expected globally; over 200 upgrade projects were added this year.
• GLP-1 HPP business accelerated significantly, growing well into the 30s organically and representing just under 12% of total revenue.
• West Vantage performance was slightly better than expected as cyber incident revenue was fully recovered, though overall decline persists due to CGM program roll-offs.
• Asia Pacific geography showed spectacular growth of 42%, led by India and China, driven by GLP-1 introductions and innovative drug development.
• Free cash flow decreased roughly 5% year-over-year due to increased receivables and inventory, but capital expenditures remained low at $125 million for the first nine months.

The company reported total revenues of $874 million, representing an 11.9% organic growth. The Proprietary Products segment was the primary driver, delivering 16.6% organic growth and accounting for approximately 53% of total company revenue (specifically $467 million from HPP components alone). Within this segment, HPP components grew 20% organically, while HPP devices grew 26% organically after excluding the impact of the SmartDOS 3.5 divestiture. Standard products contributed $163 million, showing 3% organic growth. Conversely, the West Vantage segment declined 6.6% to 7% organically, contributing approximately 17% of total revenue ($146 million), as legacy programs rolled off faster than new high-value-added programs ramped.

• Full Year 2026 Revenue: Raised to $3.41–$3.42 billion (previously $3.345–$3.38 billion), implying 11.3%–11.6% organic growth.
• Full Year 2026 Adjusted EPS: Raised to $9.38–$9.48 (previously $8.85–$9.05), representing 29%–30% year-over-year growth.
• Q4 2026 Revenue: Expected between $820–$830 million, representing 6%–7% organic growth.
• Margin Expectations: Full-year operating margins expected to expand nearly 300 basis points, driven by gross margin expansion and SG&A leverage.
• Capital Expenditures: Full-year CapEx expected between $215–$220 million, maintaining the 6%–8% of revenue corridor.
• FX Impact: Expected full-year benefit of 120 basis points; SmartDose 3.5 divestiture negatively impacts reported growth by 160 basis points.

• West Vantage segment faces structural headwinds from the roll-off of legacy programs (e.g., CGM) outpacing the ramp-up of new high-value contracts.
• Regulatory changes, such as Annex I in Europe and similar draft guidance elsewhere, may require multi-year upgrades to containment systems, though this is viewed as a tailwind for HPP components.
• GLP-1 market dynamics involve uncertainties regarding generic competition, multi-dose transitions, and oral formulations, although management remains bullish on long-term durable growth.
• Foreign exchange fluctuations pose risks, with a strengthened dollar impacting reported growth metrics.
• Operational risks include potential lumpy performance in device sales and the need to manage capacity constraints through continuous improvement efforts.

Q: Analyst Paul Knight asked about the drivers behind the spectacular 42% growth in the Asia Pacific region.

A: Management attributed the growth to a small base effect and specific opportunities in India and China, particularly driven by the introduction of GLP-1 therapies and innovative drug developments. They expressed optimism about continuing to grow in the region as more markets mature and adopt these treatments.

Q: Analyst Daniel Markowitz sought clarity on GLP-1 elastomer growth dynamics, asking if record results were one-time or sustainable given factors like the Medicare Bridge Program and generics.

A: Management confirmed there were no one-time items in the quarter. They emphasized that GLP-1s remain a transformative, durable growth driver due to expanding access via the Bridge Program, generic opportunities outside the U.S., and next-generation molecule development.

Q: Analyst Justin Bowers asked the new CEO about her top priorities for the next 6-12 months and how she plans to fortify the company's position.

A: The CEO identified two main priorities: elevating customer relationships from operational to strategic levels to improve demand planning and innovation adoption, and strengthening continuous improvement muscles through digitization and automation to drive higher efficiency and output across global sites.

Q: Analyst Doug Schenkel asked about M&A criteria and whether the high GLP-1 growth rate suggests a need to revise long-term planning assumptions.

A: The CEO stated that the bar for M&A remains incredibly high, focusing on transactions that amplify the financial profile and supply chain simplification for customers. Regarding GLP-1s, she remained bullish on the therapy class's full prospects, noting that while compounding percentages become harder, the market opportunity remains vast across current and future molecules.

Q: Analyst David Windley asked if the company would enter a multi-year elevated CapEx regime to meet demand or if existing capacity could be optimized.

A: Management reaffirmed comfort with the 6%-8% CapEx-to-revenue range. They explained that significant near-term demand can be met through continuous improvement and de-bottlenecking existing facilities, while new investments focus on upgrading finishing capacity within the current footprint rather than expanding geographically.